Table of Contents

• What is norelgestromin?
• What is the norelgestromin/ethinyl estradiol patch?
• What is it used for in studies?
• How the patch is used (dosing schedules studied)
• How well it works (what studies measured)
• Bleeding patterns, spotting, and cycle control
• Safety and side effects that were monitored
• Blood levels (pharmacokinetics) and hormone exposure
• Comparisons with pills and vaginal ring
• Patch adherence (sticking) and user compliance
• Who was in these studies?
• Important terms explained

What is norelgestromin?

Norelgestromin is a hormone used in some contraceptive patches, usually together with ethinyl estradiol (an estrogen hormone). In one study, norelgestromin is described as the active progestin (progesterone-like) metabolite of orally administered norgestimate, meaning the body can convert norgestimate into norelgestromin when taking certain birth control pills.^[1]

What is the norelgestromin/ethinyl estradiol patch?

The studied product is a transdermal contraceptive patch (a skin patch that delivers medicine through the skin). It is described in multiple trials under names such as EVRA and ORTHO EVRA, and as an ethinyl estradiol and norelgestromin transdermal patch.^[2][3][4]

One trial states each EVRA patch contains 6 mg norelgestromin and 600 micrograms ethinyl estradiol, and delivers hormones over 7 days (reported as 150 micrograms norelgestromin and 20 micrograms ethinyl estradiol per 24 hours in that study).^[2]

What is it used for in studies?

Across the trials provided, the patch was studied mainly for contraception (pregnancy prevention) and for managing abnormal uterine bleeding patterns (unexpected bleeding) in specific situations.^[5][6]

• Pregnancy prevention in healthy women, including evaluation of contraceptive efficacy (how well it prevents pregnancy), safety, and cycle control (how predictable bleeding is).^[5]

• Comparison of bleeding patterns using different schedules (traditional monthly cycling versus longer “extended” hormone use) in people with metrorrhagia (bleeding between periods).^[7]

• Treatment of irregular vaginal bleeding in people using contraceptive implants, by comparing an active hormonal patch to a placebo patch (a patch with no active hormones).^[6]

How the patch is used (dosing schedules studied)

Most studies used a “3 weeks on, 1 week off” pattern to mimic a typical 28‑day cycle: apply one patch and wear it for 7 days, replace weekly for 3 weeks, then have a patch-free week (no patch) during week 4.^[2][8][5]

• In the European experience study, participants wore the patch for 1 week and replaced it for 3 consecutive weeks, with the fourth week patch-free, and could place it on the buttock, abdomen, upper torso, or upper arm.^[2]

• In a Canadian satisfaction study, women were instructed to apply the first patch on the first day of their next menses and then follow weekly changes for 3 weeks with week 4 patch-free, keeping the change day consistent each week; patches were applied to buttocks, abdomen, upper outer arm, or upper torso (excluding breasts).^[8]

Other schedules were also studied. One trial tested an extended regimen, where patches were applied weekly for 12 consecutive weeks (84 days) followed by one patch-free week, to see whether this could reduce bleeding days compared with the standard cyclic regimen.^[7]

For treating implant-related irregular bleeding, a shorter treatment course was studied: participants applied patches for 21 days, changing the patch every 7 days (3 patches total).^[6]

How well it works (what studies measured)

Several trials evaluated effectiveness for pregnancy prevention using measures like the Pearl Index (a way to estimate pregnancy rates in contraception studies) and life table analysis (another method to estimate pregnancy probability over time). These were used to assess contraceptive efficacy in large studies of the patch.^[5][2]

In the implant-bleeding treatment trial, effectiveness is focused on bleeding control: the main outcome is the proportion of participants who report bleeding stops during treatment and remains stopped by day 14, comparing the active patch to placebo.^[6]

Bleeding patterns, spotting, and cycle control

A key topic in these trials is bleeding profile, including breakthrough bleeding and spotting (unexpected bleeding outside a planned period). In the extended-regimen trial, the main outcomes included total bleeding/spotting days and number of bleeding/spotting episodes over an 84‑day reference period.^[7]

• The extended-regimen study was designed because some people want to delay or reduce withdrawal bleeding (bleeding during the hormone-free week), and because menstrual-related symptoms like headaches or pelvic pain may occur more during the hormone-free interval; however, extended regimens can have more breakthrough bleeding, especially early on.^[7]

• Large contraceptive studies also tracked bleeding using diary cards to assess cycle control (how regular bleeding is) and compliance with patch changes.^[5][9]

• A separate randomized trial compared bleeding patterns and cycle control between EVRA and another patch (ethinylestradiol/gestodene), over 7 cycles, along with contraceptive efficacy and safety monitoring.^[10]

Safety and side effects that were monitored

Across trials, safety checks commonly included recording adverse events (side effects or medical problems during the study), physical exams, gynecologic exams, vital signs, and lab tests.^[7][5]

Patch studies also paid close attention to application site reaction (skin issues where the patch is placed), such as redness and swelling; in one bioequivalence study, skin was checked after patch removal for redness and swelling, and safety monitoring included these reactions plus ECGs and lab tests.^[3]

One study specifically investigated blood markers related to clotting, because hormonal contraception can affect the body’s clotting system. It compared the patch to an oral pill by measuring multiple coagulation parameters (blood tests related to clot formation), such as D-dimer, factor VIII, and others, in a crossover design in healthy women.^[1]

Blood levels (pharmacokinetics) and hormone exposure

Some trials focused on pharmacokinetics, meaning how much hormone gets into the blood and how it changes over time. These studies measured hormone concentrations and calculated values like Cmax (highest measured blood level), AUC (overall exposure over time), and Css (average steady level after the body reaches a stable pattern).^[3]

One study compared different manufacturing lots of the patch and compared patch exposure to an oral contraceptive (CILEST), measuring blood levels of norelgestromin, norgestrel, and ethinyl estradiol across 7‑day wear periods, with washouts between periods.^[11]

Another crossover study directly compared ORTHO EVRA (patch) vs CILEST (pill) over multiple cycles, measuring blood levels of norelgestromin, norgestrel, and ethinyl estradiol and also measuring hormone-related effects such as sex hormone-binding globulin (SHBG) and other binding proteins from the liver, to help interpret the hormone exposure results.^[12]

A separate crossover trial comparing a patch to an oral pill reported that average weekly ethinyl estradiol exposure (AUC) was higher with transdermal use than with oral use in that study, and it also reported average steady-state concentrations and peak levels for both methods; it additionally noted that patch application location did not alter steady-state or peak levels in their referenced data.^[1]

Comparisons with pills and vaginal ring

Several trials compared the patch with other contraceptive methods to understand differences in acceptability, side effects, continuation, and hormone exposure.^[4][13]

• One randomized trial compared continuation rates (staying on the method) and acceptability between the patch (OrthoEvra) and a vaginal ring (NuvaRing) over four cycles, and also looked at side effects and measures such as bacterial vaginosis scores.^[4]

• Two large trials compared the patch with oral contraceptive pills (Triphasil or Mercilon), assessing pregnancy rates (Pearl Index and life table), safety, cycle control, and compliance using diary cards.^[9][14]

• A pharmacokinetic study compared ethinyl estradiol blood levels between a patch (EVRA), a vaginal ring (NuvaRing), and an oral pill (Microgynon 30), measuring outcomes like Cmax and AUC over 21 days of active treatment and washout.^[13]

• A metabolic study compared administration routes (oral pill vs patch vs vaginal ring) over 9 weeks and measured hormone-related markers (androgens like testosterone) and glucose metabolism (how the body handles sugar) using an oral glucose tolerance test.^[15]

Patch adherence (sticking) and user compliance

Trials commonly evaluated compliance (whether participants used the patch on schedule) and adhesion (how well the patch stayed stuck to the skin). Some studies checked compliance by returned patch boxes and diary cards recording dates and sites of application and any patch detachment.^[2]

In the Canadian study, participants were instructed that only one patch should be worn at a time, that patches should not be taped down with extra adhesive, and that if a patch completely detached it should be replaced immediately and worn for the remainder of that week; adherence and dosing were tracked with diary cards.^[8]

Bioequivalence and pharmacokinetic trials also formally scored patch adhesion and checked the skin after removal to document local reactions.^[3][11]

Who was in these studies?

Many studies enrolled healthy women who needed contraception, often across multiple centers and countries, and followed them for 6–13 cycles in some large efficacy/safety studies.^[5][9]

Some studies had specific eligibility criteria. For example, a bioequivalence study included healthy women with a body mass index between 16 and 29.9 kg/m² and required certain blood values like hematocrit ≥ 36%.^[3]

The trial for implant-related bleeding enrolled women over age 18 who already used contraceptive implants and experienced abnormal bleeding, and compared an active hormonal patch to placebo over a 21-day treatment period with follow-up out to 3 months.^[6]

Important terms explained

• Transdermal: a method where medicine passes through the skin into the bloodstream (for example, a contraceptive patch).^[2]

• Combined hormonal contraception: contraception that uses both an estrogen (like ethinyl estradiol) and a progestin (like norelgestromin). In the implant-bleeding trial, the active patch is also called a combined hormonal contraceptive patch.^[6]

• Patch-free week: the week in a 4-week cycle when no patch is worn; bleeding during this time is often called withdrawal bleeding.^[2]

• Breakthrough bleeding: unplanned bleeding while using hormonal contraception, especially during weeks when hormones are being delivered.^[7]

• Spotting: light bleeding that may not require a pad or tampon; trials often count spotting days together with bleeding days.^[7]

• Pearl Index: a standard way to estimate how many pregnancies occur in a contraception study over a certain amount of time/exposure.^[5]

• Pharmacokinetics: how the body absorbs and processes a drug; patch studies measured blood hormone levels and values like Cmax, AUC, and Css.^[3]

• Bioequivalence: when two versions of a product provide very similar drug exposure in the body; one study tested whether a “faster equilibration” patch was bioequivalent to the marketed patch.^[3]

Table of Contents

• What is Drospirenone?
• Medical Uses
• Drospirenone for Contraception
• Drospirenone for Endometriosis and Adenomyosis
• Drospirenone for PCOS
• Drospirenone for Acne
• Drospirenone for Premenstrual Syndrome
• Cardiovascular Effects
• Effects on Bone Health
• Different Formulations
• Side Effects and Safety
• Special Considerations

What is Drospirenone?

Drospirenone is a synthetic progestin (a type of hormone similar to the naturally occurring hormone progesterone) used in various contraceptive formulations and hormonal treatments. What makes drospirenone unique among progestins is that it has properties similar to natural progesterone and is also a potent inhibitor of mineralocorticoid activity (meaning it can affect how your body manages salt and water) ^[1]. This gives drospirenone some distinct advantages in treating certain conditions.

Drospirenone is commonly found in birth control pills, but it’s also being studied and used as a standalone medication. It has several medical applications beyond contraception, including treatment of endometriosis, polycystic ovary syndrome (PCOS), acne, and premenstrual symptoms.

Medical Uses

Clinical trials have shown that drospirenone can be effective for several medical conditions:

• Contraception (birth control)
• Treatment of endometriosis and adenomyosis
• Management of PCOS (Polycystic Ovary Syndrome)
• Treatment of acne
• Relief of premenstrual symptoms
• Hormone replacement therapy (when combined with estradiol)

Drospirenone for Contraception

Drospirenone is widely used in oral contraceptives, both in combination with estrogens and as a progestin-only pill. Several clinical trials have demonstrated its effectiveness as a contraceptive ^[2].

Drospirenone-only pills typically contain 4 mg of drospirenone and are taken once daily. These are sometimes called “mini-pills” and are an option for women who cannot or choose not to take estrogen-containing contraceptives ^[3]. Research indicates that drospirenone effectively inhibits ovulation when taken daily, making it an effective birth control method.

Combined oral contraceptives containing drospirenone typically include drospirenone (3 mg) along with ethinyl estradiol (0.02-0.03 mg) or estetrol (15 mg). These are usually taken in a 24/4 regimen (24 days of active hormone tablets followed by 4 days of inactive tablets or low-dose tablets) ^[4].

Drospirenone-containing contraceptives work by:

• Inhibiting ovulation (preventing the release of an egg from the ovary)
• Thickening cervical mucus to prevent sperm from reaching the egg
• Thinning the uterine lining, making it less receptive to implantation

Studies are also investigating the potential use of drospirenone for emergency contraception. One clinical trial is exploring whether a single high dose of drospirenone could effectively prevent pregnancy after unprotected intercourse ^[5]. This could potentially provide an additional option for emergency contraception, particularly for women with higher BMI for whom current options may be less effective.

Drospirenone for Endometriosis and Adenomyosis

Endometriosis is a chronic condition where tissue similar to the uterine lining grows outside the uterus, causing pain and potentially infertility. Adenomyosis is a related condition where the endometrial tissue grows into the muscle wall of the uterus.

Clinical trials have shown that drospirenone may be effective in treating these conditions ^[6]. One study is investigating the use of drospirenone (4 mg daily) for 20 weeks to treat adenomyosis, with the primary goal of reducing chronic pain associated with the condition ^[7].

When combined with estetrol (a naturally occurring estrogen), drospirenone has been shown to reduce the size of ovarian endometriomas (also called “chocolate cysts”) ^[8]. This combination is being studied for its ability to:

• Reduce the size of endometriomas
• Relieve pain associated with endometriosis
• Prevent recurrence of endometriosis after surgery
• Lower levels of CA125 (a blood marker often elevated in endometriosis)

For women with endometriosis-associated pelvic pain, drospirenone has shown promise in clinical trials. It works by reducing the proliferation of endometrial tissue and decreasing the expression of Ki-67 (a marker of cell proliferation) in the endometrium ^[9].

Drospirenone for PCOS

Polycystic Ovary Syndrome (PCOS) is a common hormonal disorder affecting women of reproductive age. It’s characterized by irregular periods, excess androgen levels (male hormones), and polycystic ovaries. PCOS often presents with symptoms like hirsutism (excess hair growth), acne, and sometimes obesity and insulin resistance.

Drospirenone, particularly when combined with ethinyl estradiol, has been used to treat PCOS ^[10]. This combination works by:

• Reducing androgen levels, which helps with symptoms like excess hair growth and acne
• Regulating menstrual cycles
• Protecting the uterine lining from abnormal growth

One notable property of drospirenone is its anti-androgenic effect, which means it counteracts male hormones in the body. This makes it particularly useful for PCOS patients who often have elevated androgen levels ^[11].

A clinical trial is currently exploring whether drospirenone can be used to prevent LH (luteinizing hormone) surge in PCOS cases undergoing assisted reproductive technology (ART) cycles ^[12]. LH surge in PCOS can lead to premature ovulation or ovarian hyperstimulation syndrome during fertility treatments, so controlling it could improve outcomes.

Drospirenone for Acne

Acne is a common skin condition that can be influenced by hormonal factors. Due to its anti-androgenic properties, drospirenone-containing contraceptives have been shown to be effective in treating moderate acne ^[13].

A large clinical trial evaluated the efficacy of YAZ (drospirenone 3 mg / ethinyl estradiol 20 μg) for treating moderate acne over 6 treatment cycles. The study found that this formulation significantly reduced total acne lesion count compared to placebo ^[14].

Drospirenone helps with acne by:

• Reducing the production of sebum (skin oil) by blocking androgen effects on sebaceous glands
• Decreasing inflammation associated with acne
• Regulating hormonal fluctuations that can trigger acne breakouts

Drospirenone for Premenstrual Syndrome

Premenstrual syndrome (PMS) and its more severe form, premenstrual dysphoric disorder (PMDD), can cause significant physical and emotional symptoms before menstruation. Drospirenone has unique properties that make it effective for managing these symptoms ^[15].

Unlike other progestins, drospirenone has antimineralocorticoid activity, which means it helps the body eliminate excess water. This can reduce bloating and fluid retention commonly experienced during PMS. Its antiandrogenic properties may also help with premenstrual acne flare-ups.

A clinical trial investigated the use of drospirenone/ethinyl estradiol for premenstrual worsening of depression, showing that it can help stabilize mood fluctuations associated with the menstrual cycle ^[16].

Cardiovascular Effects

Drospirenone’s impact on the cardiovascular system is being studied in clinical trials. One study is evaluating the effect of different hormonal contraceptives, including drospirenone-only pills and combinations with estrogens, on 24-hour blood pressure in cycling women ^[17].

The antimineralocorticoid activity of drospirenone may offer advantages for certain women, particularly those with tendency toward fluid retention or slightly elevated blood pressure. However, it’s important to note that like other hormonal contraceptives, drospirenone-containing products may increase the risk of blood clots in some women, particularly those with other risk factors ^[18].

Another study examined the effects of combined estradiol and drospirenone treatment versus combined estradiol and medroxyprogesterone acetate treatment on endothelial function (the function of the cells lining blood vessels) ^[19]. This research helps to understand how different hormone combinations might affect cardiovascular health.

Effects on Bone Health

The impact of hormonal contraceptives on bone health is an important consideration, particularly for younger women who are still developing bone mass and for long-term users. Clinical trials are investigating the effects of drospirenone on bone mineral density (BMD) ^[20].

One ongoing study is comparing the effects of drospirenone-containing contraceptives with non-hormonal contraceptive methods on BMD in both adolescent and adult women ^[21]. This research will help determine whether drospirenone has any significant impact on bone development or maintenance.

For adolescents in particular, understanding the effects of hormonal contraceptives on bone health is crucial, as these are years when peak bone mass is being established.

Different Formulations

Drospirenone is available in several different formulations:

• Drospirenone-only pills: Typically containing 4 mg of drospirenone, taken daily ^[22]
• Combined with ethinyl estradiol: Common formulations include 3 mg drospirenone with either 0.02 mg or 0.03 mg ethinyl estradiol ^[23]
• Combined with estetrol: A newer formulation containing 3 mg drospirenone with 15 mg estetrol ^[24]
• Combined with estradiol: Used primarily for hormone replacement therapy in menopausal women ^[25]
• Chewable tablets: A newer formulation of drospirenone that can be chewed rather than swallowed whole ^[26]

The choice of formulation depends on the specific medical needs of the patient, potential side effects, and personal preferences. For example, women who cannot take estrogen might opt for a drospirenone-only pill, while those with PCOS might benefit from a combined formulation with ethinyl estradiol.

Side Effects and Safety

Like all medications, drospirenone can cause side effects. Common side effects may include:

• Headache
• Nausea
• Breast tenderness
• Mood changes
• Irregular bleeding or spotting, especially during the first few months
• Changes in weight

Due to its antimineralocorticoid properties, drospirenone can increase potassium levels in some people. This is generally not a problem for healthy individuals, but may be a concern for those with kidney, liver, or adrenal disease, or for those taking medications that can also increase potassium levels ^[27].

As with other hormonal contraceptives, there is a slightly increased risk of blood clots, particularly in women with other risk factors such as smoking, obesity, or a personal or family history of clotting disorders. However, the overall risk is still low for most women ^[28].

Clinical trials continue to monitor the safety of drospirenone in various populations and formulations, with many studies including specific safety outcomes to better understand its risk profile ^[29].

Special Considerations

Certain groups of patients may need special consideration when using drospirenone:

Women with obesity: Studies are investigating the pharmacokinetics (how the drug moves through the body) of drospirenone in obese women, including before and after bariatric surgery ^[30]. This research will help determine whether dosage adjustments might be needed for women with higher body weight.

Adolescents: The effect of drospirenone on bone mineral density in adolescents is being studied, as this is an important period for bone development ^[31].

Women with kidney or liver problems: Due to drospirenone’s effect on potassium levels, women with impaired kidney or liver function may need careful monitoring when using this medication ^[32].

Women taking other medications: Drospirenone can interact with certain medications, particularly those that also affect potassium levels. Always inform your healthcare provider about all medications you’re taking ^[33].

In conclusion, drospirenone is a versatile hormone medication used in various formulations for contraception and to treat several conditions including PCOS, endometriosis, acne, and premenstrual symptoms. Its unique properties make it particularly useful for certain groups of women, though like all medications, it comes with potential side effects and considerations. Always discuss with your healthcare provider to determine if a drospirenone-containing product is right for you.

Table of Contents

• What is Desmopressin?
• How Desmopressin Works
• Medical Conditions Treated with Desmopressin
• Available Formulations
• Dosage Information
• Potential Side Effects
• Precautions and Contraindications
• Use in Special Populations
• Current Research and Future Applications

What is Desmopressin?

Desmopressin (also known as DDAVP) is a synthetic version of vasopressin, a natural hormone produced by the pituitary gland. It was developed as a medication to help the body manage fluid balance and prevent excessive urination. Desmopressin is a selective agonist (activator) of the vasopressin type 2 receptor, which affects water reabsorption in the kidneys ^[1].

Common brand names for desmopressin include Minirin, Minirin Melt, Nocturin, and DDAVP. It has been used medically for decades and is on the World Health Organization’s List of Essential Medicines ^[2].

How Desmopressin Works

Desmopressin functions primarily by mimicking the action of antidiuretic hormone (ADH) released by the posterior pituitary gland. When it binds to vasopressin type 2 receptors in the kidneys, it triggers increased water reabsorption in the collecting tubules. This reduces urine production and makes the urine more concentrated ^[3].

Additionally, desmopressin stimulates the release of von Willebrand factor (VWF) and Factor VIII from endothelial cells into the bloodstream. These are important clotting factors that help prevent or control bleeding. This makes desmopressin useful for treating certain bleeding disorders ^[4].

Medical Conditions Treated with Desmopressin

Nocturnal Enuresis (Bedwetting)

Desmopressin is widely used to treat nocturnal enuresis (bedwetting) in children and adults. By reducing urine production at night, it helps prevent bedwetting episodes. Clinical trials have shown that desmopressin can significantly reduce the number of wet nights in patients with this condition ^[5].

For monosymptomatic nocturnal enuresis (bedwetting without other bladder symptoms), desmopressin is considered a first-line treatment alongside behavioral strategies. It’s particularly effective in children with reduced nighttime urinary concentration capacity ^[6].

Nocturia and Nocturnal Polyuria

Nocturia (frequent nighttime urination) caused by nocturnal polyuria (excessive urine production at night) can significantly affect sleep quality and overall well-being. Desmopressin helps reduce nighttime urination frequency by decreasing urine production.

Clinical trials have demonstrated that desmopressin significantly reduces the number of nighttime voids and increases the initial period of undisturbed sleep in patients with nocturia ^[7].

Diabetes Insipidus

Central diabetes insipidus is a condition characterized by insufficient production of vasopressin, leading to excessive thirst and urination. Desmopressin effectively treats this condition by replacing the missing hormone ^[8].

Bleeding Disorders

Desmopressin is used to treat or prevent bleeding in patients with mild to moderate hemophilia A, von Willebrand disease, and certain platelet function disorders. It works by increasing the levels of clotting factors in the blood.

Clinical trials have shown that intravenous desmopressin can increase Factor VIII levels significantly in patients with mild hemophilia A and in carriers of the hemophilia A gene ^[9]. It’s also being studied for use in platelet dysfunction associated with mild hypothermia and in patients taking aspirin or other medications that affect platelet function ^[10].

Other Medical Conditions

Research is ongoing into other potential uses for desmopressin, including:

• Reducing postoperative bleeding in cardiac and other surgeries ^[11]
• Managing bleeding in colorectal cancer patients ^[12]
• Controlling bedwetting in patients with sickle cell disease ^[13]
• Treating nocturnal enuresis in patients after bladder reconstruction surgery ^[14]
• Managing nocturnal micturition frequency in patients with Parkinson’s disease ^[15]

Available Formulations

Desmopressin is available in several different formulations:

• Oral tablets: Traditional tablets that are swallowed with water
• Oral lyophilisate (MELT): A tablet that dissolves quickly when placed under the tongue, without the need for water. This formulation has better bioavailability (0.5%) compared to traditional tablets (0.2%) ^[16]
• Nasal spray: Applied directly into the nasal cavity (has higher bioavailability at about 2%, but carries an increased risk of hyponatremia) ^[17]
• Injectable solution: For intravenous or subcutaneous administration, usually in hospital settings

The choice of formulation depends on the condition being treated, patient preference, and the specific needs of the patient. For example, the MELT formulation may be more suitable for children who have difficulty swallowing tablets ^[18].

Dosage Information

Dosages of desmopressin vary depending on the condition being treated, the patient’s age, weight, and the specific formulation being used:

• For nocturnal enuresis in children: Typically 120-240 μg of oral lyophilisate or 0.2-0.4 mg of tablet formulation taken at bedtime ^[19]
• For nocturia in adults: Usually 25-50 μg of oral lyophilisate or 0.1-0.4 mg of tablet formulation taken at bedtime ^[20]
• For hemophilia A and von Willebrand disease: Typically 0.3 μg/kg administered intravenously or subcutaneously ^[21]
• For diabetes insipidus: Dosing is individualized based on response, typically starting with lower doses and titrating upward as needed ^[22]

It’s important to follow your doctor’s prescription exactly. Taking more than the prescribed dose can lead to serious side effects, particularly water retention and hyponatremia (low sodium levels in the blood).

Potential Side Effects

Like all medications, desmopressin can cause side effects. Common side effects include:

• Headache
• Nausea
• Mild abdominal pain
• Facial flushing
• Nasal congestion (with nasal spray formulation)

The most serious potential side effect is hyponatremia (low sodium levels in the blood), which can occur if there’s excessive water retention. Symptoms of hyponatremia include:

• Headache
• Nausea and vomiting
• Confusion
• Seizures
• In severe cases, coma

The risk of hyponatremia is higher in elderly patients and those who drink large amounts of fluid while taking desmopressin. Clinical trials have monitored sodium levels closely, particularly during the first week of treatment ^[23].

Other less common side effects reported in clinical trials include:

• Increased blood pressure
• Dizziness
• Diarrhea
• Dry mouth (xerostomia)
• Dry eyes (xerophthalmia)
• Blurred vision
• Difficulty swallowing
• Constipation
• Rhinitis

Precautions and Contraindications

Desmopressin should be used with caution in certain situations and is contraindicated (should not be used) in others:

Contraindications:

• Hyponatremia (low sodium levels)
• Habitual or psychogenic polydipsia (excessive drinking)
• Severe renal impairment (creatinine clearance below 50 ml/min)
• Congestive heart failure
• Known hypersensitivity to desmopressin

Use with caution in patients with:

• Conditions associated with fluid and electrolyte imbalance
• Moderate renal impairment
• Cardiovascular disease
• Hypertension
• Cystic fibrosis
• Advanced age (elderly patients are at increased risk of hyponatremia)

Fluid intake should be limited to a minimum from 1 hour before until 8 hours after taking desmopressin to reduce the risk of water intoxication and hyponatremia ^[24].

Use in Special Populations

Children

Desmopressin is widely used in children for the treatment of nocturnal enuresis. The oral lyophilisate (MELT) formulation is often preferred for children as it doesn’t require water for administration and has better bioavailability. Studies have shown that desmopressin is effective and generally well-tolerated in children when used at appropriate doses ^[25].

Elderly Patients

Elderly patients are at increased risk of developing hyponatremia with desmopressin treatment. Lower doses may be required, and sodium levels should be monitored carefully, especially at the start of treatment. Fluid restriction is particularly important in this population ^[26].

Patients with Sickle Cell Disease

Research is ongoing into the use of desmopressin for treating nocturnal enuresis in patients with sickle cell disease. Preliminary studies suggest it may be effective, but more research is needed to fully establish its safety and efficacy in this population ^[27].

Pregnant Women

There are limited data on the use of desmopressin during pregnancy. It should only be used if the potential benefit justifies the potential risk to the fetus. Always consult with your healthcare provider if you are pregnant or planning to become pregnant.

Current Research and Future Applications

Ongoing research is exploring new applications for desmopressin:

• Cancer Treatment: Studies are investigating the potential role of desmopressin in cancer treatment, particularly for breast and colorectal cancers. Preliminary research suggests it might help reduce the formation of metastases by affecting the survival of circulating tumor cells ^[28].
• Surgical Applications: Research is examining the use of desmopressin to reduce bleeding in various surgical procedures, including cardiac valve surgery, rhinoplasty, and surgeries in patients with acquired von Willebrand disease ^[29].
• Personalized Medicine: Studies are looking at genetic factors that influence response to desmopressin, particularly in hemophilia A patients and carriers. This could lead to more personalized treatment approaches in the future ^[30].

As research continues, our understanding of desmopressin’s effects and potential applications continues to grow. This may lead to improved treatment protocols and new therapeutic uses in the future.

Table of Contents

• What is Desmopressin Acetate?
• How Desmopressin Works
• Medical Uses
  • Nocturnal Enuresis (Bedwetting)
  • Nocturia in Adults
  • Bleeding Disorders
  • Other Medical Uses
• Dosage Forms and Administration
• Side Effects and Safety Considerations
• Effectiveness and Treatment Response
• Special Populations
• Ongoing Research

What is Desmopressin Acetate?

Desmopressin acetate (also known as DDAVP, Minirin, Nocturin, or Minirin Melt) is a synthetic version of vasopressin, a hormone naturally produced by the pituitary gland. Desmopressin is a medication used to treat several conditions related to water balance in the body and certain bleeding disorders. It’s a modified form of the natural hormone that has enhanced antidiuretic (water-retaining) effects while reducing other unwanted effects of natural vasopressin ^[1].

How Desmopressin Works

Desmopressin works primarily by binding to vasopressin type 2 receptors (V2R) in the kidneys. When it attaches to these receptors, it causes the kidneys to reabsorb more water, reducing urine production. This helps the body retain water and produces more concentrated urine. In addition to its effects on the kidneys, desmopressin also causes endothelial cells to release von Willebrand factor (VWF) and factor VIII into the bloodstream, which are important proteins for blood clotting ^[2].

Medical Uses

Nocturnal Enuresis (Bedwetting)

One of the most common uses of desmopressin is for treating nocturnal enuresis (bedwetting) in children. This condition affects approximately 18% of younger school-age children in Egypt and is a worldwide health problem. For children with primary monosymptomatic nocturnal enuresis (bedwetting without daytime urinary symptoms), desmopressin helps by reducing the amount of urine produced during sleep ^[3].

Desmopressin has shown effectiveness in reducing the frequency of bedwetting episodes in children. Studies have demonstrated that it can significantly decrease the number of wet nights compared to placebo. The medication works quickly, often showing results within days of starting treatment ^[4].

In one study comparing desmopressin to oxybutynin (another medication used for urinary issues), both medications were evaluated for their efficacy and safety in treating nocturnal enuresis in children. The study measured outcomes such as frequency of nocturnal enuresis, urinary incontinency, and various side effects ^[5].

Desmopressin is also being studied for bedwetting in children with special conditions, such as sickle cell disease, where nighttime bedwetting affects up to 30% of children ^[6].

Nocturia in Adults

Desmopressin is used to treat nocturia (excessive nighttime urination) in adults. Nocturia can be caused by various factors, including nocturnal polyuria (excessive urine production at night), reduced bladder capacity, or a combination of both ^[7].

For adults with nocturia due to nocturnal polyuria, desmopressin helps by decreasing nighttime urine production. This can lead to fewer nighttime voids, longer periods of undisturbed sleep, and improved quality of life ^[8].

A randomized, double-blind, placebo-controlled study investigated the efficacy and safety of several doses of the melt formulation of desmopressin in adult patients with nocturia. The study found that desmopressin reduced the number of nocturnal voids and increased the initial period of undisturbed sleep compared to placebo ^[9].

Desmopressin is also being studied for treating nocturia in patients with benign prostatic hyperplasia (BPH). In a clinical trial, desmopressin was added to tamsulosin (a medication commonly used for BPH) to evaluate its effects on nocturia and nocturnal polyuria in these patients ^[10].

Bleeding Disorders

Desmopressin is used to treat or prevent bleeding in certain bleeding disorders. It’s particularly useful for:

• Mild to moderate hemophilia A: Desmopressin increases factor VIII levels in the blood, which helps with blood clotting ^[11].
• Von Willebrand disease: Desmopressin increases von Willebrand factor levels, which are important for platelet function and blood clotting ^[12].
• Platelet function disorders: Desmopressin can improve platelet function in some cases ^[13].

In patients with bleeding disorders, desmopressin is often given before surgical procedures to reduce the risk of excessive bleeding. The response to desmopressin varies between individuals, so a therapeutic test is usually performed before using it for treatment ^[14].

A study investigating genetic factors influencing the factor VIII response to desmopressin in carriers of hemophilia A found that the medication increases the level of endogenous factor VIII, thus avoiding the need for potentially immunogenic exogenous factor VIII. It’s also cheaper than factor VIII concentrates and more widely available in pharmacies in hospitals with emergency rooms and surgical facilities ^[15].

Other Medical Uses

Desmopressin has several other medical uses, including:

• Diabetes insipidus: A condition where the body can’t regulate fluid balance, resulting in excessive thirst and urination ^[16].
• Treating bleeding in patients on antiplatelet therapy: Desmopressin may help counteract the effects of medications like aspirin that affect platelet function ^[17].
• Diagnostic testing: Desmopressin is used in tests to evaluate kidney function and the body’s ability to concentrate urine ^[18].

Researchers are also exploring new potential uses for desmopressin. For example, a study is investigating whether desmopressin administered before surgery in breast cancer patients could help reduce the spread of cancer cells that might be released during tumor manipulation ^[19].

Dosage Forms and Administration

Desmopressin is available in several forms:

• Tablets: Oral tablets taken by mouth, typically in doses ranging from 0.1 mg to 0.4 mg ^[20].
• Oral lyophilisate (melt): A tablet that dissolves under the tongue without water. These are available in various strengths, including 25 μg, 50 μg, 60 μg, 120 μg, and 240 μg ^[21].
• Nasal spray: Sprayed into the nostrils ^[22].
• Injectable solution: Administered intravenously or subcutaneously by a healthcare provider ^[23].

The dosage and form of desmopressin depend on the condition being treated, the patient’s age, weight, and response to the medication. For example, for children with nocturnal enuresis, the typical oral lyophilisate dose might be 120 μg at bedtime, while for adults with nocturia, the dose might range from 25 μg to 100 μg ^[24].

A bioequivalence study compared the single-dose relative bioavailability of TEVA and Aventis Pharmaceuticals (DDAVP®) 0.2 mg desmopressin acetate tablets following a 0.8 mg dose under fasting conditions. The study evaluated maximum observed concentration (Cmax) and area under the concentration-time curve (AUC) to determine if the formulations were equivalent ^[25].

Side Effects and Safety Considerations

Desmopressin is generally well-tolerated, but it can cause side effects, including:

• Headache
• Nausea
• Mild abdominal cramps
• Facial flushing
• Nasal congestion (with nasal spray)

The most serious potential side effect is hyponatremia (low sodium levels in the blood) due to water retention. This is more likely to occur if excessive fluids are consumed while taking desmopressin. Symptoms of hyponatremia can include headache, nausea, vomiting, confusion, seizures, and in severe cases, coma ^[26].

To reduce the risk of hyponatremia, patients are advised to:

• Limit fluid intake from 1 hour before until 8 hours after taking desmopressin
• Have serum sodium levels monitored, especially when starting treatment
• Be aware of symptoms of hyponatremia and seek medical attention if they occur

Desmopressin should be used with caution in certain groups, including elderly patients, young children, and those with conditions that might increase the risk of water retention or hyponatremia ^[27].

In a long-term safety and tolerability study of desmopressin orally disintegrating tablets for nocturia, researchers monitored adverse events, changes in laboratory values and vital signs, and the incidence and severity of hyponatremia during treatment ^[28].

Effectiveness and Treatment Response

The effectiveness of desmopressin varies depending on the condition being treated and individual factors. For nocturnal enuresis in children, studies have shown that about 70% of patients experience a significant reduction in wet nights while using the medication ^[29].

For nocturia in adults, clinical trials have demonstrated that desmopressin can reduce the number of nighttime voids by about 40-50% and increase the initial period of undisturbed sleep by 1-2 hours ^[30].

The response to desmopressin in bleeding disorders is more variable and depends on the specific disorder and the individual’s baseline levels of clotting factors. In mild to moderate hemophilia A, desmopressin typically increases factor VIII levels by 2-4 times the baseline level ^[31].

Factors that may influence the response to desmopressin include:

• Age
• Gender
• Weight
• Specific genetic mutations (in bleeding disorders)
• Baseline levels of the affected hormones or factors
• Concurrent medications

A study on the pharmacokinetics and pharmacodynamics of desmopressin in children found that the dose response may vary based on age and weight. This highlights the importance of individualizing treatment based on patient characteristics ^[32].

Special Populations

Children

Desmopressin is commonly used in children for treating nocturnal enuresis. The dosage is typically adjusted based on the child’s weight and age. For children younger than 5 years, desmopressin is generally not recommended for bedwetting as spontaneous resolution is common at this age ^[33].

A study comparing posterior tibial nerve stimulation to desmopressin in children with primary monosymptomatic nocturnal enuresis found that both treatments were viable options, with desmopressin being particularly useful when there are no contraindications or concerns about side effects ^[34].

Elderly Patients

Elderly patients may be more susceptible to hyponatremia when taking desmopressin. Lower starting doses and careful monitoring of fluid intake and serum sodium levels are recommended for this population ^[35].

Patients with Renal Impairment

Desmopressin should be used with caution in patients with renal (kidney) impairment, as they may have altered response to the medication and increased risk of side effects ^[36].

Patients with Bleeding Disorders

For patients with bleeding disorders, the response to desmopressin depends on the specific disorder and genetic factors. A therapeutic test is usually performed to assess the individual’s response before using desmopressin for treatment ^[37].

A study on genetic factors influencing the factor VIII response to desmopressin in carriers of hemophilia A found that certain genetic variations may affect how well patients respond to the medication ^[38].

Ongoing Research

Research on desmopressin continues to explore new uses and optimize treatment protocols for existing indications. Some areas of current research include:

• Combination therapies: Studies are investigating the combination of desmopressin with other medications for enhanced efficacy. For example, a trial is looking at adding desmopressin to tamsulosin for treating nocturnal polyuria in patients with benign prostatic obstruction ^[39].
• Genetic factors affecting response: Researchers are studying how genetic variations influence the response to desmopressin, particularly in bleeding disorders like hemophilia A ^[40].
• Cancer applications: Studies are examining whether desmopressin might help reduce cancer spread during surgery by affecting the survival of tumor cells released into circulation ^[41].
• Optimizing dosing regimens: Research is focused on finding the most effective dosing regimens while minimizing side effects, particularly in special populations like children and the elderly ^[42].
• Novel formulations: Development of new formulations, such as orally disintegrating tablets (melts), aim to improve convenience and absorption ^[43].

A pharmacokinetic/dynamic study is investigating the characteristics of desmopressin melt in nocturia patients compared to healthy volunteers and children. The study aims to understand if differences in response are related to pathophysiological factors involved in nocturia, if there are age/gender/size differences, and if it’s possible to identify patients who are likely to develop hyponatremia ^[44].

Table of Contents

• What is Chlormadinone Acetate?
• Medical Uses
• How It Works
• Administration and Dosage
• Comparison with Other Progestins
• Side Effects and Considerations
• Potential Benefits
• Current Research Studies

What is Chlormadinone Acetate?

Chlormadinone acetate is a synthetic progestin (a laboratory-made version of the natural female hormone progesterone). It belongs to a specific category called C-21 progestins. The medication is often sold under brand names such as Belara® (when combined with ethinylestradiol) and Luteran®^[1].

Medical Uses

Based on clinical trial data, chlormadinone acetate is used for several medical purposes:

• Contraception (birth control): When combined with ethinylestradiol (a synthetic estrogen) in oral contraceptive pills like Belara®, it prevents pregnancy^[2].
• Hormone Therapy: Used in postmenopausal women as part of hormone replacement therapy, typically combined with 17β-estradiol^[1].

How It Works

Chlormadinone acetate works in multiple ways in the body:

• It has progestogenic effects (similar to natural progesterone)^[1].
• It possesses antiandrogenic properties, which means it blocks the effects of male hormones in the body^[2].
• It also has some glucocorticoid effects, which relates to metabolism and immune response^[2].

Administration and Dosage

According to the clinical trials reviewed:

• For contraception: Typically administered as 2 mg chlormadinone acetate combined with 30 mcg ethinylestradiol (Belara®), taken as one tablet daily for 21 days followed by a 7-day break^[2].
• For postmenopausal hormone therapy: Used at a dosage of 5 mg/day orally, often combined with 0.05 mg/day transdermal (through the skin) 17β-estradiol^[1].

Comparison with Other Progestins

Clinical trials have compared chlormadinone acetate with other progestins:

• Natural progesterone: One study compared chlormadinone acetate to natural progesterone in postmenopausal hormone therapy, looking at effects on gene expression in blood cells^[1].
• Drospirenone: Another study compared chlormadinone acetate (in Belara®) with drospirenone (in Yasmin®) for contraceptive use, focusing particularly on body weight changes and other side effects^[2].

While chlormadinone acetate has glucocorticoid and antiandrogenic effects, drospirenone (another progestin) has antimineralocorticoid (affects fluid balance) and antiandrogenic effects^[2].

Side Effects and Considerations

Clinical trials have investigated several potential side effects of chlormadinone acetate:

• Body weight changes: This was a primary focus of comparison between chlormadinone acetate and drospirenone in contraceptive use^[2].
• Vaginal spotting: Breakthrough bleeding between periods was monitored in studies^[2].
• Androgenic effects: Because of its antiandrogenic properties, chlormadinone acetate might cause fewer androgenic side effects (like acne or excess hair growth) compared to some other progestins^[2].
• Blood pressure effects: These were monitored in clinical trials^[2].
• Headaches and gastrointestinal effects: These were also tracked as potential side effects^[2].

Potential Benefits

Based on its properties, chlormadinone acetate may offer certain advantages:

• Antiandrogenic effects: May be beneficial for women with conditions related to excess androgen activity, such as acne or hirsutism (excess hair growth)^[2].
• Potential for minimal weight gain: Research has specifically looked at body weight changes with this medication, suggesting this might be a consideration in its use^[2].

Current Research Studies

Chlormadinone acetate has been involved in several clinical trials:

1. Postmenopausal Hormone Therapy Study: Comparing natural progesterone to chlormadinone acetate in combination with estradiol, examining effects on gene expression in blood cells, quality of life, and various blood markers over 12 months^[1].
2. Contraceptive Comparison Study: Comparing contraceptive pills containing chlormadinone acetate (Belara®) with those containing drospirenone (Yasmin®), specifically looking at body weight changes, contraceptive effectiveness, side effects, and user satisfaction over 6 months^[2].

These studies aim to better understand how different progestins work in the body and help healthcare providers select the most appropriate medication for each individual patient’s needs.

Table of Contents

• What is Micronized Progesterone?
• Medical Uses
• Administration
• Effectiveness
• Side Effects and Safety
• Ongoing Research

What is Micronized Progesterone?

Micronized progesterone is a form of the hormone progesterone that has been processed to create very small particles. This micronization process makes the hormone easier for your body to absorb and use^[1]. Progesterone is a naturally occurring hormone in the female body, playing a crucial role in the menstrual cycle and maintaining pregnancy.

Medical Uses

Micronized progesterone is primarily used in the field of reproductive medicine. Its main applications include:

• Assisted Reproductive Technology (ART): It’s used to support the luteal phase (the period after ovulation) during fertility treatments^[1].
• Intrauterine Insemination (IUI): Some studies are investigating its use in IUI treatments^[1].
• In Vitro Fertilization (IVF): It’s commonly used in IVF procedures, particularly in frozen embryo transfer cycles^[2].
• Unexplained Infertility: Research is being conducted on its potential benefits for couples with unexplained infertility^[1].

Administration

Micronized progesterone can be administered in different ways:

• Vaginal Use: The most common form is vaginal capsules or gel. This method allows for direct absorption by the uterus^[1][2].
• Oral Use: In some cases, it may be taken orally, although this is less common in fertility treatments^[2].

The dosage and duration of treatment can vary depending on the specific medical condition and treatment protocol. For example, in some IVF protocols, patients might use 200mg three times daily or 400mg twice daily^[2].

Effectiveness

The effectiveness of micronized progesterone in fertility treatments is an active area of research. Some key points include:

• In IVF treatments, progesterone supplementation is considered standard care and has been shown to improve pregnancy outcomes^[1].
• For IUI treatments, research is ongoing to determine if progesterone supplementation can increase live birth rates^[1].
• In frozen embryo transfer cycles, progesterone is crucial for preparing the uterus for embryo implantation^[2].

Side Effects and Safety

Micronized progesterone is generally considered safe for use in fertility treatments. However, like all medications, it can have side effects. Common side effects may include:

• Drowsiness
• Dizziness
• Abdominal pain
• Nausea
• Breast tenderness

It’s important to note that extensive safety data is available from its use in IVF treatments. Both short-term and long-term assessments of offspring health have not revealed any significant risks associated with progesterone use in reproductive medicine^[1].

Ongoing Research

Several clinical trials are currently underway to further investigate the use of micronized progesterone in various fertility treatments:

• The LUMO study is examining whether progesterone support can improve live birth rates in couples undergoing IUI with mild ovarian stimulation^[1].
• Another study is comparing different formulations and dosages of vaginal micronized progesterone in frozen embryo transfer cycles^[2].
• Researchers are also investigating the impact of progesterone levels on pregnancy outcomes in frozen embryo transfer cycles^[2].

These ongoing studies aim to optimize the use of micronized progesterone in various fertility treatments, potentially improving success rates and patient outcomes.

Table of Contents

• What is PERTECHNETATE (99MTC) SODIUM?
• Medical Use in Early-Stage Ovarian Cancer
• How Does It Work?
• How is It Administered?
• Current Clinical Trial
• Who is Eligible for the Trial?
• Potential Benefits
• Precautions and Exclusions

What is PERTECHNETATE (99MTC) SODIUM?

PERTECHNETATE (99MTC) SODIUM, also known as Sodium pertechnetate (99mTc), is a radioactive substance used in medical imaging^[1]. It’s classified as a radiopharmaceutical, which means it’s a drug containing a radioactive isotope used for diagnostic or therapeutic purposes in nuclear medicine.

Medical Use in Early-Stage Ovarian Cancer

This substance is being studied for its potential use in detecting sentinel lymph nodes in patients with early-stage epithelial ovarian cancer^[1]. Epithelial ovarian cancer is a type of cancer that begins in the cells lining the ovaries. Early detection of cancer spread to lymph nodes is crucial for proper staging and treatment planning.

How Does It Work?

PERTECHNETATE (99MTC) SODIUM works as a tracer. When injected near the tumor site, it travels through the lymphatic system and collects in the sentinel lymph nodes – the first lymph nodes where cancer cells are likely to spread^[1]. Special cameras can then detect the radioactive signal, helping surgeons locate these important nodes.

How is It Administered?

The drug is administered as an injectable solution^[1]. It’s typically injected near the tumor site before surgery. The maximum daily dose is 400,000,000 Bq (becquerels), which is a unit used to measure radioactivity^[1].

Current Clinical Trial

A clinical trial is currently underway to evaluate the effectiveness of PERTECHNETATE (99MTC) SODIUM in sentinel node detection for early-stage ovarian cancer^[1]. The study aims to:

• Assess how well the tracer can detect sentinel lymph nodes
• Evaluate the precision of sentinel lymph node detection
• Study the lymphatic drainage patterns in ovarian cancer
• Compare the performance of different detection techniques
• Examine the anatomical distribution of sentinel lymph nodes

Who is Eligible for the Trial?

The trial is open to patients who meet specific criteria^[1]:

• Women with suspected or confirmed early-stage epithelial ovarian cancer
• No evidence of cancer spread to lymph nodes or distant sites on imaging
• Able to undergo surgery
• 18 years of age or older
• Not pregnant or breastfeeding

Potential Benefits

If successful, this technique could offer several benefits^[1]:

• More accurate staging of ovarian cancer
• Improved detection of small metastases in lymph nodes
• Potentially less extensive surgery if unnecessary lymph node removal can be avoided
• Better understanding of how ovarian cancer spreads through the lymphatic system

Precautions and Exclusions

Certain conditions may prevent participation in the trial^[1]:

• Advanced stage ovarian cancer (FIGO stage III or IV)
• History of vascular surgery or radiation therapy in the pelvic or para-aortic area
• Hypersensitivity to the active ingredient or iodine allergy
• Clinical hyperthyroidism or certain thyroid conditions

It’s important to note that while this treatment shows promise, it’s still under investigation. Patients should discuss all potential risks and benefits with their healthcare provider before considering participation in any clinical trial.

Table of Contents

• Overview of BP1.4979
• Understanding Binge Eating Disorder (BED)
• The Clinical Study on BP1.4979
• Eligibility Criteria for the Study
• Study Endpoints: Measuring Effectiveness
• Potential Implications for Patients

Overview of BP1.4979

BP1.4979 is an investigational drug being studied for the treatment of binge eating disorder (BED) in women. Its scientific name is N-[4-[2-[4-(3-CYANOPHENYL)PIPERAZIN-1-YL]ETHYL]CYCLOHEXYL]-3-METHOXYPROPANAMIDE^[1]. This medication is being developed as a potential new option for patients struggling with moderate to severe BED symptoms.

Understanding Binge Eating Disorder (BED)

Binge eating disorder is a serious mental health condition characterized by recurring episodes of eating large quantities of food in a short period, often to the point of discomfort. People with BED typically feel a loss of control during these episodes and may experience feelings of shame, distress, or guilt afterward^[1]. It’s important to note that BED is different from other eating disorders like bulimia nervosa or anorexia nervosa.

The Clinical Study on BP1.4979

A clinical trial is being conducted to assess the effectiveness and safety of BP1.4979 for treating BED. Here are some key points about the study:

• It’s a Phase II study, which means it’s testing the drug’s effectiveness and looking for side effects in a larger group of people^[1].
• The study is double-blind and placebo-controlled. This means that neither the participants nor the researchers know who is receiving the actual drug and who is receiving a placebo (a substance with no active ingredients). This helps ensure unbiased results^[1].
• The dosage being tested is 15 mg, taken twice daily (abbreviated as BID, which stands for “bis in die” in Latin, meaning twice a day)^[1].
• The study focuses on female patients aged 18 to 65 with moderate to severe BED symptoms^[1].

Eligibility Criteria for the Study

To participate in the study, patients must meet certain criteria. Some key inclusion criteria are:

• Female, aged 18-65 years^[1].
• Diagnosed with BED according to DSM-5 criteria (DSM-5 is the Diagnostic and Statistical Manual of Mental Disorders, 5th edition, used by mental health professionals to diagnose conditions)^[1].
• At least two binge-eating days per week and at least 8 episodes during the 2 weeks prior to starting the study medication^[1].

Some exclusion criteria (reasons why someone cannot participate) include:

• Current diagnosis of bulimia nervosa or anorexia nervosa^[1].
• Recent use of psychostimulants for weight loss or dieting^[1].
• History of certain psychiatric disorders or ongoing alcohol addiction treatment^[1].
• Pregnancy or inadequate contraception use^[1].

Study Endpoints: Measuring Effectiveness

The study will measure several outcomes to determine if BP1.4979 is effective. The main (primary) endpoint is:

• The change in the total number of binge-eating episodes per week, comparing the 2 weeks before starting treatment to the last 2 weeks of the 8-week treatment period^[1].

Secondary endpoints (additional measures of effectiveness) include:

• Changes in food addiction symptoms, measured by the Yale Food Addiction Scale^[1].
• Overall improvement in BED symptoms, assessed by the Clinical Global Impression scale^[1].
• Changes in the number of binge-eating days per week^[1].

Potential Implications for Patients

If BP1.4979 proves to be safe and effective in this study, it could potentially offer a new treatment option for women struggling with binge eating disorder. However, it’s important to remember that this is still an investigational drug, and more research will be needed before it can be approved for general use.

Patients with BED should continue to work with their healthcare providers to manage their condition using currently approved treatments and therapies. If you’re interested in participating in clinical trials for BED, you can discuss this with your doctor or search for trials in your area on reputable clinical trial registry websites.

Table of Contents

• Overview of the trials
• Ovarian cancer studies
• Liver disease and cirrhosis studies
• Septic shock and kidney injury study
• Other trials using Human Serum Albumin
• Main endpoints and what they mean
• Who may take part

Overview of the trials

The trial data show several studies of Human Serum Albumin in very different clinical settings, including cancer, liver disease, critical illness, and eye injury.^{[1][2][3][4][5][6]}

Most trials are Phase 3, with some Phase 2 studies and one Phase 1/2 trial.^{[1][2][3][4][5][6][7]}

These studies are interventional, which means researchers give a treatment or procedure and then measure the results.^{[1][2][3][4][5][6][7]}

Ovarian cancer studies

Two trials study sentinel lymph node detection in early-stage ovarian cancer, including epithelial ovarian cancer in early stages.^[1][2]

In these studies, Human Serum Albumin appears as part of the tracer or detection approach used during surgery or mapping of lymph nodes.^[1][2]

The main goal is to see how well the sentinel lymph node technique finds cancer spread, using measures such as the negative predictive value and the global detection rate.^[1][2]

One trial compares the sentinel node technique with pelvic and aortic lymphadenectomy, which is surgery to remove lymph nodes and use that as the gold standard for checking spread.^[1]

The ovarian cancer studies are in Phase 3 and Phase 2, with planned enrollment of 200 and 62 patients.^[1][2]

Liver disease and cirrhosis studies

Several trials focus on cirrhosis, which is long-term scarring of the liver, and its complications.^[3][4][5][6]

One Phase 3 study in critically ill patients with septic shock and high risk of acute kidney injury tests whether Human Serum Albumin can reduce severe kidney injury during the first 7 days after shock begins.^[3]

Another Phase 2 trial in decompensated cirrhosis studies a combination of Human Serum Albumin and enoxaparin, with a main focus on safety and tolerability, including treatment-emergent adverse events, pulmonary edema, severe thrombocytopenia, and major bleeding.^[4]

A Phase 3 trial in decompensated cirrhosis and AKI 1B or greater compares intravenous Human Serum Albumin with saline solution to see whether kidney function improves and whether acute kidney injury resolves.^[5]

Two related Phase 3 cirrhosis trials look at a personalized approach to Human Serum Albumin therapy and measure liver-related outcomes such as variceal bleeding, ascites, spontaneous bacterial peritonitis, infection needing hospitalization, acute kidney injury, and overt hepatic encephalopathy.^[6][7]

One of these cirrhosis studies was withdrawn, while the other remains authorised.^[6][7]

Another completed Phase 3 trial in cirrhosis with ACLF-1b, ACLF-2, or ACLF-3a studied whether standard medical treatment plus PE-A 5% improves 90-day overall survival compared with standard treatment alone.^[8]

Septic shock and kidney injury study

The septic shock trial is for critically ill patients with a high risk of acute kidney injury (AKI), which means sudden kidney damage.^[3]

The study measures the incidence of AKI reaching KDIGO stage 2-3 during the first 7 days after septic shock starts.^[3]

This is a Phase 3 randomized controlled trial, meaning patients are assigned to treatment groups by chance.^[3]

Other trials using Human Serum Albumin

One Phase 1/2 solid tumor trial includes Human Serum Albumin among several infusion drugs used in the study program.^[9]

This trial is mainly designed to test safety, dose-limiting toxicities, serious treatment-emergent adverse events, and anti-tumor activity in patients with recurrent and/or refractory solid tumors.^[9]

Another Phase 2 trial in severe eye chemical burns uses ALBUTEIN 50 g/L as part of a subconjunctival injection protocol with mesenchymal stromal cells, and the main endpoint is absence of corneal perforation.^[10]

This eye study is focused on preserving the eyeball 6 months after the first injection.^[10]

Main endpoints and what they mean

A primary outcome is the main result the researchers want to measure.^[1]

In these trials, primary outcomes include negative predictive value, detection rate, incidence of severe AKI, safety events, kidney recovery, overall survival, and absence of corneal perforation.^{[1][2][3][4][5][8][9][10]}

Some studies use terms like overall survival, which means how long people live after treatment starts, and objective response rate, which means how many patients have their tumors shrink or disappear.^[8][9]

Other studies look at liver-related events such as ascites, variceal bleeding, spontaneous bacterial peritonitis, and hepatic encephalopathy, which is confusion caused by severe liver disease.^[6][7]

Who may take part

The studies include people with early-stage ovarian cancer, cirrhosis, decompensated cirrhosis, septic shock, acute kidney injury, recurrent and/or refractory solid tumors, and severe eye chemical burns.^{[1][2][3][4][5][6][7][8][9][10]}

Some trials are for hospitalized or critically ill patients, while others focus on surgical or cancer staging settings.^[1][3][5][8]

Each study has its own rules for who can join, based on the disease stage and the clinical situation described in the trial record.^[1][3][5][8]

Table of Contents

• What is ETHYL ESTERS OF IODISED FATTY ACIDS FROM POPPYSEED OIL?
• Medical Uses
• How It Works
• How It’s Administered
• Current Clinical Trials
• Potential Side Effects and Precautions
• Conclusion

What is ETHYL ESTERS OF IODISED FATTY ACIDS FROM POPPYSEED OIL?

ETHYL ESTERS OF IODISED FATTY ACIDS FROM POPPYSEED OIL is a medical product derived from poppyseed oil. It’s also known by its brand name Lipiodol Ultra Fluide^[1]. This substance is an iodine-containing contrast medium, which means it’s used to make certain body structures more visible during imaging procedures^[2].

Medical Uses

This medication has several important medical applications:

• Diagnostic Imaging: It’s used in various imaging procedures to help doctors see certain body structures more clearly^[1].
• Infertility Treatment: It’s being studied for its potential to improve fertility in women with at least one open fallopian tube^[3].
• Cancer Treatment: It’s used in the treatment of certain types of liver cancer, specifically hepatocellular carcinoma (HCC)^[4].
• Osteoarthritis Treatment: It’s being investigated for use in treating knee osteoarthritis^[5].

How It Works

The way this medication works depends on its specific use:

• As a Contrast Agent: When used in imaging, it helps make certain body structures more visible on X-rays or other imaging tests^[2].
• In Fertility Treatments: When used in a procedure called hysterosalpingography (HSG), it may help clear blockages in the fallopian tubes, potentially improving fertility^[3].
• In Cancer Treatment: When used in a procedure called transarterial chemoembolization (TACE), it helps deliver chemotherapy drugs directly to liver tumors while also blocking their blood supply^[4].

How It’s Administered

The method of administration varies depending on its use:

• Intrauterine Use: For fertility treatments, it’s injected into the uterus during a hysterosalpingography procedure^[3].
• Intraarterial Use: For liver cancer treatment, it’s injected into the arteries that supply blood to the tumor^[4].
• Injection: For knee osteoarthritis treatment, it’s injected directly into the knee joint^[5].

Current Clinical Trials

Several clinical trials are currently investigating the use of this medication:

• LIPIOJOINT-2 Trial: This study is examining its effectiveness in treating knee osteoarthritis through a procedure called Genicular Arteries Embolization (GAE)^[5].
• H2Oil-2 Study: This trial is comparing oil-based (using this medication) and water-based contrast media for hysterosalpingography in infertile women^[3].
• TACE-3 Trial: This study is investigating its use in combination with other treatments for intermediate-stage liver cancer^[4].

Potential Side Effects and Precautions

As with any medication, there are potential side effects and precautions to be aware of:

• Allergic Reactions: Some people may be allergic to iodine or poppy seed oil^[1].
• Thyroid Function: Due to its iodine content, it may affect thyroid function. Patients with thyroid disorders should inform their doctor^[3].
• Pregnancy and Breastfeeding: It should not be used in pregnant or breastfeeding women unless absolutely necessary^[4].
• Other Precautions: It may not be suitable for people with certain conditions such as severe kidney or liver problems, or certain heart conditions^[5].

Conclusion

ETHYL ESTERS OF IODISED FATTY ACIDS FROM POPPYSEED OIL is a versatile medical product with applications in diagnostic imaging, fertility treatments, and cancer therapy. While it shows promise in various areas, it’s important to remember that many of its uses are still being studied in clinical trials. As with any medical treatment, it should only be used under the guidance of a healthcare professional who can weigh its potential benefits against any risks for your specific situation.

Table of Contents

• What is Autologous Adipose Tissue-Derived Stromal Vascular Fraction (ADSVF)?
• Conditions Being Treated with ADSVF
• How ADSVF Works
• How ADSVF is Administered
• Current Clinical Trials
• Safety and Side Effects
• Future Research and Potential

What is Autologous Adipose Tissue-Derived Stromal Vascular Fraction (ADSVF)?

Autologous Adipose Tissue-Derived Stromal Vascular Fraction (ADSVF) is an innovative medical treatment that uses cells from a patient’s own fat tissue. The term “autologous” means the cells come from the patient’s own body, while “adipose tissue” refers to fat tissue. Stromal vascular fraction (SVF) is a complex mixture of cells found within fat tissue, including stem cells, immune cells, and other supportive cells^[1].

Conditions Being Treated with ADSVF

Research is ongoing to explore the potential of ADSVF in treating various medical conditions. Current clinical trials are investigating its use in:

• Urethral stricture: A narrowing of the urethra that can cause difficulty urinating^[2].
• Diabetic foot ulcers: Chronic wounds that occur in people with diabetes^[3].
• Scarred vocal folds: Damage to the vocal cords that can cause voice problems^[4].
• Perianal Crohn’s disease fistulas: Abnormal connections between the intestine and skin near the anus in patients with Crohn’s disease^[5].

How ADSVF Works

ADSVF is believed to work through several mechanisms:

1. Regeneration: The stem cells in ADSVF may help regenerate damaged tissues.
2. Anti-inflammatory effects: ADSVF contains cells that can reduce inflammation in the treated area.
3. Angiogenesis: ADSVF may promote the formation of new blood vessels, improving blood supply to the affected area.
4. Immunomodulation: The cells in ADSVF can help regulate the immune response, potentially beneficial in conditions like Crohn’s disease.

How ADSVF is Administered

The process of ADSVF treatment typically involves:

1. Fat harvesting: A small amount of fat is taken from the patient’s body, usually from the abdomen or thighs.
2. Processing: The fat tissue is processed to isolate the stromal vascular fraction.
3. Injection: The ADSVF is then injected into the affected area. For example:
   • For urethral strictures, it’s injected near the urethra^[2].
   • For diabetic foot ulcers, it’s injected around the wound^[3].
   • For vocal fold scars, it’s injected into the vocal folds^[4].
   • For Crohn’s disease fistulas, it’s injected around the fistula tracts^[5].

Current Clinical Trials

Several clinical trials are currently underway to evaluate the safety and effectiveness of ADSVF for various conditions:

• A study for recurrent urethral stricture, comparing ADSVF injection to standard treatment^[2].
• A trial for diabetic foot ulcers that haven’t responded to standard care^[3].
• An investigation into ADSVF for treating scarred vocal folds and improving voice quality^[4].
• A study on the use of ADSVF combined with microfat for treating perianal fistulas in Crohn’s disease^[5].

Safety and Side Effects

As ADSVF uses the patient’s own cells, the risk of rejection is low. However, potential side effects may include:

• Pain or discomfort at the injection site
• Bruising or swelling
• Infection (though rare)

The ongoing clinical trials are closely monitoring patients for any adverse effects to ensure the safety of this treatment^[2][3][4][5].

Future Research and Potential

ADSVF is an exciting area of research in regenerative medicine. Future studies may explore its use in other conditions and further refine the treatment process. As research progresses, we may gain a better understanding of how factors like the composition of ADSVF and individual patient characteristics affect treatment outcomes^[5].

While ADSVF shows promise, it’s important to note that these treatments are still experimental. Patients should discuss all treatment options with their healthcare providers to determine the best approach for their individual situation.

Men in the study will be assigned to receive either the medicine combination or no treatment. The treatment period lasts about 16 weeks. During this time, the medicines are given by injection, with follitropin alfa given under the skin and chorionic gonadotrophin given into a muscle. The study then compares sperm concentration at the end of treatment.

In the study, one group receives letrozole together with the usual fertility treatment, while the other group receives the usual treatment without letrozole. Treatment is given during one egg collection cycle, and any embryos made from that cycle may be transferred fresh or frozen and used later within about one year. The study then follows the pregnancy outcomes after these embryo transfers. The study also looks at related conditions such as adenomyosis, a condition in which tissue similar to the lining of the womb grows into the womb muscle.

The study is designed to see whether letrozole can improve reproductive results in this setting and to collect information on pregnancy, birth, and any problems that may happen during pregnancy. It also records pain after egg collection and quality of life around the time of embryo transfer.